查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2112269

美國臨床前CRO市場規模、佔有率和趨勢分析報告：按服務、開發階段、適應症、模型類型、最終用途和細分市場預測（2026-2033年）

U.S. Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Bioanalysis & DMPK studies, Toxicology Testing, Compound Management), By Development Stage, By Indication, By Model Type, By End-use, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國臨床前CRO市場概述

美國臨床前 CRO 市場預計到 2025 年將達到 17 億美元，從 2026 年的 18 億美元成長到 2033 年的 31 億美元，2026 年至 2033 年的年複合成長率（CAGR）為 7.7%。

受藥物研發日益複雜、對先進療法的需求不斷成長以及製藥和生物技術公司外包業務擴張等因素的推動，該市場正經歷穩步成長。臨床前CRO在支持藥物研發早期階段發揮著至關重要的作用，它們提供的服務包括藥理學、毒理學、生物分析、DMPK測試、安全性評估、療效測試、疾病建模以及IND申請支持試驗。

此外，美國臨床前CRO產業受益於強大的生物製藥產業、大量的研發投入、先進的實驗室基礎設施以及清晰的法規環境。市場成長的另一個關鍵促進因素是人們對個人化醫療和標靶治療日益成長的關注。這些方法針對特定的患者群體、疾病亞型或基因譜，因此全面的臨床前評估至關重要。申辦者越來越需要複雜的體外和體內模型，以便在臨床試驗前評估藥物的作用機轉、療效、安全性、藥物動力學和毒性。這一趨勢正在推動對專業CRO服務的需求，尤其是在腫瘤學、罕見疾病、神經系統疾病、自體免疫疾病和遺傳性疾病領域。

此外，生技藥品、細胞和基因療法、放射性藥物以及其他創新療法的研發管線不斷擴展，進一步推動了美國臨床前CRO市場的發展。這些先進療法通常需要比傳統小分子化合物更複雜的測試，包括生物分佈研究、免疫抗原性評估、載體安全性評估、劑量最佳化和長期毒性研究。由於美國中小型生物技術公司缺乏進行這些測試所需的完善內部基礎設施，因此外包給CRO是一種切實可行且經濟的解決方案。

技術應用也是推動成長的關鍵因素。美國臨床前合約研究組織（CRO）正擴大採用先進技術，例如3D細胞培養模型、類器官、患者來源的異種移植模型、人工智慧資料分析、成像平台、高通量篩檢和轉化疾病模型。這些創新提高了臨床前數據的臨床相關性，使申辦方能夠在進行人體臨床試驗前做出更明智的決策。例如，3D腫瘤模型和先進腫瘤學平台的應用正在改善癌症治療的早期評估。癌症、阿茲海默症、代謝性疾病和心血管疾病等慢性疾病的日益普遍也進一步推動了市場擴張。隨著製藥公司投入越來越多的資源開發這些疾病的治療方法，對臨床前試驗的需求持續推動市場成長。

此外，美國FDA的嚴格規定要求在提交IND申請前提供安全性、毒性和有效性數據，這使得申辦方必須與熟悉監管要求的經驗豐富的CRO合作。因此，在藥物研發活動的活躍、外包趨勢的日益成長、先進療法研發管線的不斷擴展以及對專業臨床前模型需求的不斷成長的推動下，美國臨床前CRO市場預計將迎來新的成長機會。

目錄

第1章 研究方法和範圍

第2章執行摘要

第3章：美國臨床前CRO市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 科技情勢
  • 定價模式分析
  • 關稅影響分析
  • 價值鏈分析
  • 市場分析工具

第4章：美國臨床前CRO市場：按服務類型分類的估算與趨勢分析

  • 美國臨床前CRO市場：基於服務的趨勢分析
  • 美國臨床前CRO市場估算與預測：依服務類型分類，2021-2033年
  • 生物分析和DMPK研究
    • in vitro ADME
    • In vivo PK
  • 毒性測試
    • GLP
    • 非GLP規範
  • 化合物管理
    • 製程研究與開發
    • 客製合成
    • 其他
  • 化學
    • 藥物化學
    • 計算化學
  • 安全藥理學市場估算與預測（2021-2033）
  • 其他

第5章：美國臨床前CRO市場：依研發階段分類的估算與趨勢分析

  • 美國臨床前CRO市場：依研發階段分類的波動分析
  • 美國臨床前CRO市場估算與預測：依研發階段分類，2021-2033年
  • 目標已找到
  • 臨床前最佳化、療效和藥物動力學/藥效學。
  • IND申請的安全測試（GLP）
  • 生物分析與分析

第6章：美國臨床前CRO市場：依適應症分類的估算與趨勢分析

  • 美國臨床前CRO市場：按適應症分類的趨勢分析
  • 美國臨床前CRO市場估算與預測：按適應症分類，2021-2033年
  • 腫瘤學
  • 中樞神經系統（CNS）
  • 感染疾病
  • 心血管疾病
  • 代謝性疾病
  • 罕見疾病
  • 其他

第7章：美國臨床前CRO市場：按模式類型分類的估算與趨勢分析

  • 美國臨床前CRO市場：按模式類型分類的趨勢分析
  • 美國臨床前CRO市場估算與預測：依模式類型分類，2021-2033年
  • In Vitro
  • In Vivo
  • Ex Vivo

第8章：美國臨床前CRO市場：依最終用途分類的估算與趨勢分析

  • 美國臨床前CRO市場：按最終用途分類的趨勢分析
  • 美國臨床前CRO市場估算與預測：依應用領域分類，2021-2033年
  • 製藥和生物製藥公司
  • 醫療設備製造商
  • 學術和研究機構
  • 其他

第9章 競爭情勢

  • 主要公司分類
    • 市場領導
    • 新興企業
  • 2025年市場估值分析（熱圖分析）
  • 公司簡介
    • Eurofins Scientific
    • ICON plc
    • Medpace Holdings, Inc.
    • Charles River Laboratories
    • PPD（Thermo Fisher Scientific, Inc.）
    • SGS SA（SGS Societe Generale de Surveillance SA.）
    • Intertek Group plc（IGP）
    • Labcorp
    • Crown Bioscience
Product Code: GVR-4-68040-257-3

U.S. Preclinical CRO Market Summary

The U.S. preclinical CRO market size was valued at USD 1.7 billion in 2025 and is projected to grow from USD 1.8 billion in 2026 to USD 3.1 billion by 2033, at a CAGR of 7.7% from 2026 to 2033. The market is experiencing steady growth, driven by factors including the complexities of drug discovery, increased demand for advanced therapies, and greater outsourcing by pharmaceutical and biotechnology firms. Preclinical CROs are crucial to supporting early-stage drug development, offering services such as pharmacology, toxicology, bioanalysis, DMPK studies, safety assessment, efficacy testing, disease modeling, and IND-enabling studies.

Moreover, the U.S. preclinical CRO industry benefits from a robust biopharmaceutical sector, significant R&D investments, advanced laboratory infrastructure, and a well-defined regulatory environment. Besides, one of the key drivers of market growth is the increased focus on personalized medicine and targeted therapies. These approaches target specific patient populations, disease subtypes, or genetic profiles, necessitating thorough preclinical evaluations. Sponsors are increasingly seeking sophisticated in vitro and in vivo models to evaluate mechanisms of action, efficacy, safety, pharmacokinetics, and toxicity prior to clinical trials. This trend is fueling the requirement for specialized CRO expertise, particularly in oncology, rare diseases, neurological disorders, autoimmune diseases, and genetic disorders.

In addition, the expanding pipeline of biologics, cell and gene therapies, radiopharmaceuticals, and other innovative modalities is further supporting the U.S. preclinical CRO market. These advanced therapies typically require more intricate testing than conventional small molecules, including biodistribution studies, immunogenicity assessment, vector safety evaluations, dose optimization, and long-term toxicology studies. Many small to mid-sized biotech firms in the U.S. lack the comprehensive in-house infrastructure for such studies, making outsourcing to CROs a viable and economical solution.

Technology adoption is one of the significant contributors to growth as U.S. preclinical CROs are increasingly employing advanced techniques, such as 3D cell culture models, organoids, patient-derived xenograft models, AI-driven data analytics, imaging platforms, high-throughput screening, and translational disease models. These innovations enhance the clinical relevance of preclinical data and enable sponsors to make more informed decisions before human trials. For instance, the use of 3D tumor models and sophisticated oncology platforms is enhancing the early assessment of cancer therapies. The market is further fueled by the rising prevalence of chronic diseases, including cancer, Alzheimer's disease, metabolic disorders, and cardiovascular conditions. As drug developers funnel more resources into therapies for these illnesses, the demand for preclinical testing continues to drive the market growth.

Furthermore, stringent U.S. FDA regulations necessitating safety, toxicity, and efficacy data prior to IND submission compel sponsors to collaborate with experienced CROs familiar with regulatory requirements. Thus, the U.S. preclinical CRO market is expected to witness new growth opportunities driven by robust drug development activities, rising outsourcing trends, an expanding array of advanced therapy pipelines, and an increasing need for specialized preclinical models.

U.S. Preclinical CRO Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. preclinical CRO market report based on service, development stage, indication, model type, and end use:

  • Service Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Bioanalysis and DMPK studies
    • In vitro ADME
    • In-vivo PK
  • Toxicology Testing
    • GLP
    • Non-GLP
  • Compound Management
    • Process R&D
    • Custom Synthesis
    • Others
  • Chemistry
    • Medicinal Chemistry
    • Computation Chemistry
  • Safety Pharmacology
  • Others
  • Development Stage Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Target Discovery
  • Preclinical Optimization, Efficacy & PK/PD
  • IND-Enabling Safety (GLP)
  • Bioanalysis & Analytics
  • Indication Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Oncology
  • CNS
  • Infectious Diseases
  • Cardiovascular Diseases
  • Metabolic Disorders
  • Rare Diseases
  • Others
  • Model Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • In Vitro
  • In Vivo
  • Ex Vivo
  • End Use Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Pharmaceutical and Biopharmaceutical Companies
  • Medical Device Companies
  • Academic and Research Institutes
  • Others

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Service
    • 1.2.2. Development Stage
    • 1.2.3. Indication
    • 1.2.4. Model Type
    • 1.2.5. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Bottom-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Preclinical CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Force Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Preclinical CRO Market: Service Estimates & Trend Analysis

  • 4.1. U.S. Preclinical CRO Market, By Service: Segment Dashboard
  • 4.2. U.S. Preclinical CRO Market, By Service: Movement Analysis
  • 4.3. U.S. Preclinical CRO Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million/Billion)
  • 4.4. Bioanalysis and DMPK studies
    • 4.4.1. Bioanalysis and DMPK studies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.4.2. In vitro ADME
      • 4.4.2.1. In vitro ADME Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.4.3. In vivo PK
      • 4.4.3.1. In vivo PK Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.5. Toxicology Testing
    • 4.5.1. Toxicology Testing Market Estimates & Forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.5.2. GLP
      • 4.5.2.1. GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.5.3. Non-GLP
      • 4.5.3.1. Non-GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.6. Compound Management
    • 4.6.1. Compound Management Market Estimates & Forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.6.2. Process R&D
      • 4.6.2.1. Process R&D Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.6.3. Custom Synthesis
      • 4.6.3.1. Custom Synthesis Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.6.4. Others
      • 4.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.7. Chemistry
    • 4.7.1. Chemistry Market Estimates & Forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.7.2. Medicinal Chemistry
      • 4.7.2.1. Medicinal Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.7.3. Computational Chemistry
      • 4.7.3.1. Computational Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.8. Safety Pharmacology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.8.1. Safety Pharmacology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.9. Others
    • 4.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 5. U.S. Preclinical CRO Market: Development Stage Estimates & Trend Analysis

  • 5.1. U.S. Preclinical CRO Market, By Development Stage: Segment Dashboard
  • 5.2. U.S. Preclinical CRO Market, By Development Stage: Movement Analysis
  • 5.3. U.S. Preclinical CRO Market Estimates & Forecasts, By Development Stage, 2021 - 2033 (USD Million/Billion)
  • 5.4. Target Discovery
    • 5.4.1. Target Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5. Preclinical Optimization, Efficacy & PK/PD
    • 5.5.1. Preclinical Optimization, Efficacy & PK/PD Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.6. IND-Enabling Safety (GLP)
    • 5.6.1. IND-Enabling Safety (GLP) Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.7. Bioanalysis & Analytics
    • 5.7.1. Bioanalysis & Analytics Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 6. U.S. Preclinical CRO Market: Indication Estimates & Trend Analysis

  • 6.1. U.S. Preclinical CRO Market, By Indication: Segment Dashboard
  • 6.2. U.S. Preclinical CRO Market, By Indication: Movement Analysis
  • 6.3. U.S. Preclinical CRO Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million/Billion)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.5. CNS
    • 6.5.1. CNS Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.6. Infectious Diseases
    • 6.6.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.7. Cardiovascular Diseases
    • 6.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.8. Metabolic Disorders
    • 6.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.9. Rare Diseases
    • 6.9.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.10. Others
    • 6.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 7. U.S. Preclinical CRO Market: Model Type Estimates & Trend Analysis

  • 7.1. U.S. Preclinical CRO Market, By Model Type: Segment Dashboard
  • 7.2. U.S. Preclinical CRO Market, By Model Type: Movement Analysis
  • 7.3. U.S. Preclinical CRO Market Estimates & Forecasts, By Model Type, 2021 - 2033 (USD Million/Billion)
  • 7.4. In Vitro
    • 7.4.1. In vitro Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.5. In Vivo
    • 7.5.1. In Vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.6. Ex Vivo
    • 7.6.1. Ex Vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 8. U.S. Preclinical CRO Market: End Use Estimates & Trend Analysis

  • 8.1. U.S. Preclinical CRO Market, By End Use: Segment Dashboard
  • 8.2. U.S. Preclinical CRO Market, By End Use: Movement Analysis
  • 8.3. U.S. Preclinical CRO Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million/Billion)
  • 8.4. Pharmaceutical and Biopharmaceutical Companies
    • 8.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5. Medical Device Companies
    • 8.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.6. Academic and Research Institutions
    • 8.6.1. Academic and Research Institutions Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.7. Others
    • 8.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 9. Competitive Landscape

  • 9.1. Key Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
  • 9.3. Company Profiles
    • 9.3.1. Eurofins Scientific
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. ICON plc
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Medpace Holdings, Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Charles River Laboratories
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. PPD (Thermo Fisher Scientific, Inc.)
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. SGS SA (SGS Societe Generale de Surveillance SA.)
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Intertek Group plc (IGP)
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Labcorp
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Crown Bioscience
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Preclinical CRO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million/Billion)
  • Table 4 U.S. Preclinical CRO Market Estimates and Forecasts, by Development Stage, 2021 - 2033 (USD Million/Billion)
  • Table 5 U.S. Preclinical CRO Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million/Billion)
  • Table 6 U.S. Preclinical CRO Market Estimates and Forecasts, by Model Type, 2021 - 2033 (USD Million/Billion)
  • Table 7 U.S. Preclinical CRO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million/Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2025 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2025 (USD Billion)
  • Fig. 16 U.S. Preclinical CRO Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Preclinical CRO Market: Service outlook and key takeaways
  • Fig. 20 U.S. Preclinical CRO Market: Service movement analysis
  • Fig. 21 In vitro ADME Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 22 In-vivo PK Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 23 Toxicology Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 24 GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 25 Non-GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 26 Compound Management Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 27 Process R&D Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 28 Custom Synthesis Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 29 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 30 Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 31 Medicinal Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 32 Computation Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 33 Safety Pharmacology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 34 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 35 U.S. Preclinical CRO Market: Development Stage outlook and key takeaways
  • Fig. 36 U.S. Preclinical CRO Market: Development Stage movement analysis
  • Fig. 37 Target Discovery
  • Fig. 38 Preclinical Optimization, Efficacy & PK/PD
  • Fig. 39 IND-Enabling Safety (GLP)
  • Fig. 40 Bioanalysis & Analytics
  • Fig. 41 U.S. Preclinical CRO Market: Indication outlook and key takeaways
  • Fig. 42 U.S. Preclinical CRO Market: Indication movement analysis
  • Fig. 43 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 44 CNS Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 45 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 46 Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 47 Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 48 Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 49 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 50 U.S. Preclinical CRO Market: Model Type outlook and key takeaways
  • Fig. 51 U.S. Preclinical CRO Market: Model Type movement analysis
  • Fig. 52 In Vitro Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 53 In Vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 54 Ex Vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 55 U.S. Preclinical CRO Market: End Use outlook and key takeaways
  • Fig. 56 U.S. Preclinical CRO Market: End Use movement analysis
  • Fig. 57 Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 58 Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 59 Academic and Research Institutions Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 60 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • Fig. 61 Key company categorization
  • Fig. 62 Service heat map analysis
  • Fig. 63 Strategic framework